Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosolized rAAT in Alpha 1-Antitrypsin Deficiency
NCT00157092Phase 2Completed
- Sponsor
- Takeda
- Start
- Mar 2004
- Primary completion
- Oct 2004
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of recombinant alpha-1 antitrypsin in alpha-1 antitrypsin deficiency (AATD) (3 arms), sponsored by Takeda. Primary endpoint: Alpha 1-antitrypsin levels in epithelial lining fluid at Day 8. Started Mar 2004; status: completed.
02
Drugs
recombinant alpha-1 antitrypsin
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT00157092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00157092.